Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Cardiomyopathy to Cardiovascular Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Cardiomyopathy to Cardiovascular Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Cardiomyopathy Therapeutics Clinical Trials 35
Prominent Drugs 37
Clinical Trial Profile Snapshots 38
Appendix 245
Abbreviations 245
Definitions 245
Research Methodology 246
Secondary Research 246
About GlobalData 246
Contact Us 247
Source 247

List of Tables
Cardiomyopathy Therapeutics, Global, Clinical Trials by Region, 2018* 7
Cardiomyopathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Cardiomyopathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Cardiomyopathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Cardiomyopathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Cardiomyopathy Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Cardiomyopathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Cardiomyopathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Cardiomyopathy to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 17
Cardiomyopathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Cardiomyopathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Cardiomyopathy to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 22
Cardiomyopathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Cardiomyopathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Cardiomyopathy Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Cardiomyopathy Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Cardiomyopathy Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Cardiomyopathy Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Cardiomyopathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Cardiomyopathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32
Cardiomyopathy Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Cardiomyopathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Cardiomyopathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

List of Figures
Cardiomyopathy Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Cardiomyopathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Cardiomyopathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Cardiomyopathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Cardiomyopathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Cardiomyopathy Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Cardiomyopathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Cardiomyopathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Cardiomyopathy to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 16
Cardiomyopathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Cardiomyopathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Cardiomyopathy to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 21
Cardiomyopathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Cardiomyopathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Cardiomyopathy Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Cardiomyopathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Cardiomyopathy Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Cardiomyopathy Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Cardiomyopathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Cardiomyopathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32
Cardiomyopathy Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Cardiomyopathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Cardiomyopathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37
GlobalData Methodology 246

Companies Mentioned
- MyoKardia Inc
- Gilead Sciences Inc
- Stemedica Cell Technologies Inc
- Sanofi
- Eiger BioPharmaceuticals Inc
- Heart Metabolics Ltd
- Array BioPharma Inc
- Mesoblast Ltd
- Cytokinetics Inc
- Bayer AG